MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma

Globally, gastroesophageal adenocarcinoma are among the most common causes of cancer related deaths.1 Treatment still largely relies on conventional cytotoxic agents which are only limitedly effective in the majority of patients.2,3 According to a comprehensive molecular analysis by The Cancer Genome Atlas (TCGA) Network, gastric cancer (including gastroesophageal junction cancer) can be classified into four subgroups based on its molecular characteristics: Epstein-Barr virus (EBV)-infected tumors, microsatellite instable (MSI) tumors, genomically stable (GS) tumors and chromosomally instable (CIN) tumors.

Source: Cancer Treatment Reviews - April 26, 2020 Category: Cancer & Oncology Authors: M.J.M. van Velzen, S. Derks, N.C.T. van Grieken, N. Haj Mohammad, H.W.M. van Laarhoven Tags: Anti-tumour Treatment Source Type: research